NCT01444456

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Electronic Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia: An International Prospective Observational Study (eAQUA)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,262 (actual)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, international, prospective, observational study of patients who are receiving systemic chemotherapy for solid tumour cancers (breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal, pancreatic, esophageal or gastric) and who are receiving darbepoetin alfa (Aranesp®) or other erythropoiesis-stimulating agent (ESA) to treat symptomatic anaemia. Quality of Life will be assessed electronically with the aim of estimating improvement in quality of life for those patients receiving darbepoetin alfa (Aranesp®) who also have an increase in haemoglobin (Hb) of ≥1 g/dL

Detailed description

Before enrolling participants, each country was assigned to either cohort 1 (patients receiving only darbepoetin alfa) or cohort 2 (patients receiving any ESA). Cohort 2 was assigned only to those countries in which local regulations did not permit observational study participation by patients receiving a specific agent in a drug class.

Conditions

• Anemia
• Breast Cancer
• Cancer
• Colorectal Cancer
• Lung Cancer
• Ovarian Cancer
• Prostate Cancer
• Solid Tumors
• Bladder Cancer
• Endometrial Cancer
• Renal Cancer
• Pancreatic Cancer
• Esophageal Cancer
• Gastric Cancer

Timeline

• Start date: 2011-10-01
• Primary completion: 2013-08-01
• First posted: 2011-09-30
• Last updated: 2017-03-20
• Results posted: 2014-08-15

Locations

117 sites across 9 countries: Austria, Belgium, France, Germany, Greece, Italy, Netherlands, Poland, Romania